bluebird bio Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Good day, everybody, and thank you for joining us at the Bank of America Virtual Health Care Conference. My name is Jason Gerberry. I cover SMID cap biotech at BofA, and I am pleased to be introducing our next company presenter, bluebird bio. We're joined by Nick Leschly, CEO, and several members of the management team will also be dialing into the call as well.
So bluebird bio is focused on developing complex and potentially curative therapies for underserved populations. I'd argue the company's gene and cell therapies are still in the relative early innings as a therapeutic modality, and blue is one of the pioneers looking to blaze a trail for these therapies and work through some logistical and technical challenges in bringing these new therapeutic modalities to market.
And so pleased to be introducing the company, and Nick has some initial prepared remarks, and then we'll jump into Q&A. So Nick, all yours.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
